Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Developments in Gene Therapy for Ocular DiseasesSAE Media Group reports: The Ophthalmic Drugs Conference will be focusing on developments in Gene Therapy for Ocular Diseases
By: SAE Media Group The conference will convene on 21 – 22 November 2022 in London, UK, this year attendees will hear from industry giants about the developments being made in the ophthalmics and gene therapy field. Interested parties can register at http://www.ophthlamicdrugs.com/ The 5th annual conference will have a more in-depth discussion about the Developments in Gene Therapy for Ocular Diseases, with presentations and keynote speakers. Use of Antisense Oligonucleotides for the Treatment of Inherited Retinal Diseases
Led by: Aniz Girach, Chief Medical Officer, ProQR Therapeutics Lumevoq Gene Therapy in Leber Hereditary Optic Neuropathy
Led by: Magali Taiel, Chief Medical Officer, Gensight Biologics Ocular Inflammation associated with Gene and Cell Therapy
Led by: Virginia Calder, Professor of Ocular Immunology, University College London Strengthening the Therapeutic Landscape for Inherited Retinal Diseases Using Genome Editing with AAV Vectors & CRISPR/Cas9 Technologies
Led by: Daniel Chung, Chief Medical Officer, Sparing Vision To find out more about the line – up of the esteemed speakers for the conference and to download a complimentary brochure please visit http://www.ophthlamicdrugs.com/ For sponsorship enquiries contact Andrew Gibbons on +44 (0) 20 7827 6156 or email: agibbons@smi- For media enquiries or a press pass contact Marketing, Simi Sapal on +44 (0) 20 7827 6162 or email ssapal@smi-online.co.uk Ophthalmic Drugs 21-22 November 2022 London, UK #OphthalmicDrugs Sponsor: The Technology Partnership | Celanese http://www.ophthlamicdrugs.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|